drugset / Trial / NCT02784392

Efficacy, Safety, and Pharmacokinetics (PK) Study of Ulimorelin in Patients With Enteral Feeding Intolerance (EFI): The PROMOTE Trial

NCT02784392

Phase 2 Completed 120 enrolled Lyric Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the effect Ulimorelin in patients with enteral feeding intolerance.

Timeline

Start
2016-10
Primary completion
2018-03
Completion
2018-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Metoclopramide Small molecule
Subject Ulimorelin Small molecule Intravenous

Indications

No indication recorded.